February 23, 2017 Liz Amdahl

Molecular Pathways: Mucins and Drug Delivery in Cancer

Chinthalapally V. Rao, Naveena B. Janakiram and Altaf Mohammed

Published 23 February 2017

DOI: 10.1158/1078-0432.CCR-16-0862

Abstract

Over the past few decades, clinical and preclinical studies have clearly demonstrated the role of mucins in tumor development. It is well established that mucins form a barrier impeding drug access to target sites, leading to cancer chemoresistance. Recently gained knowledge regarding core enzyme synthesis has opened avenues to explore the possibility of disrupting mucin synthesis to improve drug efficacy. Cancer cells exploit aberrant mucin synthesis to efficiently mask the epithelial cells and ensure survival under hostile tumor microenvironment conditions. However, O-glycan synthesis enzyme core 2 beta 1,6 N-acetylglucosaminyltransferase (GCNT3/C2GnT-2) is overexpressed in Kras-driven mouse and human cancer, and inhibition of GCNT3 has been shown to disrupt mucin synthesis. This previously unrecognized developmental pathway might be responsible for aberrant mucin biosynthesis and chemoresistance. In this Molecular Pathways article, we briefly discuss the potential role of mucin synthesis in cancers, ways to improve drug delivery and disrupt mucin mesh to overcome chemoresistance by targeting mucin synthesis, and the unique opportunity to target the GCNT3 pathway for the prevention and treatment of cancers. Clin Cancer Res; 23(6); 1–6. ©2016 AACR.

Click here to access full article.

Supported File Formats:


  • – Non Proprietary (JPG, TIF)
  • – 3D Histech (MRXS)
  • – Aperio (SVS, AFI, eSlideManager)
  • – Hamamatsu (NDPI, NDPIS)
  • – Leica (SVS, SCN, LIF)
  • – Mikroscan (TIF)
  • – Nikon (ND2)
  • – Olympus (VSI)
  • – Perkin Elmer (QPTIFF, Vectra TIF)
  • – Philips IMS
  • – Zeiss (CZI)

Don’t see the format you’re looking for? Contact us to make a request

CLOSE
Thank you for signing-up. Please check your email for link to access webinar recording.